Plan B, FDA Acting Commissioner Used To Spotlight Conflict-Of-Interest Bill
Executive Summary
Rep. Henry Waxman (D-Calif.) is highlighting the escalating controversy surrounding the proposed OTC switch of Plan B to build support for a bill intended to limit the politicization of scientific decisions
You may also be interested in...
Plan B Delay Draws Criticism From Congress, Academia, FDA Official
FDA's handling of Barr's application to switch Plan B over the counter could elicit heightened external scrutiny of the agency's ability to make drug approval decisions based solely on science and public health
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials